Skip to main content

Table 4 Summary of birth prevalence for Morquio A

From: A systematic review of the prevalence of Morquio A syndrome: challenges for study reporting in rare diseases

 

Birth prevalence

per 10, 000

Evidence of consanguinity

Evidence of ethnicity founder effect

Representative of whole country

Study period

Age at diagnoses

Cases born during study period Æ—

Denominator = live births

Recommended enzymatic analysis

Quality

Australia KOL [27]

1 per 253,000

0.04*

NR

NR

Y

24 (1980-2013)

0-45

Y

Y

YÆ—

ungraded

Germany [32]

1 per 263,000*

0.0380*

NR

Y

Y

15 (1980-1995)

NR

NR

Y

YÆ—

medium

UAE (Emirates) [25]

1 per 71, 000

0.14*

Y

NR

N

15 (1995-2010)

NR

Y

Y

YÆ—

medium

Australia [31]

1 per 201, 000

0.0497*

NR

NR

Y

17 (1980-1996)

0-19

NÆ—

Y

Y

medium

Canada (BC) [30]

1 per 207,000*

0.048*

NR

NR

N

24 (1972-1996)

NR

NR

Y

Y

medium

Japan (POR) [35]

1 per 500,000

0.02*

NR

NR

unclear

20 (1991-2011)

NR

NR

Y

Y

ungraded

Australia (W) [18]

1 per 641, 000

0.0156*

NR

NR

N

27 (1969-1996)

NR

Y

Y

unclear

medium

Netherlands [37]

1 per 459, 000*

0.022*

NR

NR

Y

26 (1970-1996)

NR

Y

Y

unclear

medium

Taiwan [38]

1 per 304,000

0.033*

NR

NR

Y

20 (1984-2004)

NR

NR

Y

unclear

low

UK (NI) [17]

1 per 76, 000

0.13*

NR

NR

N

27 (1958-1985)

NR

NR

Y

unclear

low

Brazil (KOL) [36]

1 per 1,179,000*

0.009*

NR

NR

Y

9 (2004-2013)

1-6

Y

Y

NR

ungraded

Canada (BC) [41]

1 per 216, 000

0.046*

NR

NR

N

34 (1952-1986)

NR

NR

Y

NR

low

  1. Abbreviations: BC British Columbia, KOL Key Opinion Leader, POR Patient organisation representative, N No, NI Northern Ireland, NR Not recorded, UAE United Arab Emirates, UK United Kingdom, W West, Y Yes. *Calculated by authors; Æ—assumed from the study period and age at diagnosis; Ç‚Fibroblast & Leukocyte based analysis.